Abstract
A novel approach to the preparation of the α-emitting radionuclide 223Ra was proposed to be applied for direct treatment of bone metastases and targeted alpha-radioimmunotherapy. The tandem generator system based on ion exchange columns was developed for isolation of 223Ra in the form of 223Ra-EDTA complexes in 0.9 % NaCl solutions at pH = 7.4–8.0. Advantages of the method for routine laboratory work and clinical implementations are discussed.
Similar content being viewed by others
References
Henriksen G, Breistøl K, Bruland ØS, Fodstad Ø, Larsen RH (2002) Significant antitumor effect from bone-seeking, α-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model. Cancer Res 62:3120–3125
Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW, Westlin J-E, Salberg G, Bruland ØS (2005) First clinical experience with α-emitting 223Ra in the Treatment of Skeletal Metastases. Clin Cancer Res 11:4451–4459
Larsen RH, Saxtorph H, Skydsgaard M, Borrebaek J, Jonasdottir TJ, Bruland ØS, Klastrup S, Harling R, Ramdahl T (2006) Radiotoxicity of the alpha-emitting bone-seeker 223Ra injected intravenously into mice: histology, clinical chemistry and hematology. In Vivo 20:325–332
Bruland ØS, Nilsson S, Fisher DR, Larsen RH (2006) High-linear energy transfer irradiation targeted to skeletal metastases by the α-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 12:6250s–6257s
Harrison MR, Wong TZ, Armstrong AJ, George DJ (2013) 223Ra chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res 5:1–14
Carrasquillo JA, O’Donoghue JA, Pandit-Taskar N, Humm JL, Rathkopf DE, Slovin SF, Williamson MJ, Lacuna K, Aksnes A-K, Larson SM, Scher HI, Morris MJ (2013) Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging 40:1384–1393
Jadvar H, Quinn DI (2013) Targeted α-particle therapy of bone metastases in prostate cancer. Clin Nucl Med 38:966–971
Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall’Oglio M, Franzén L, Coleman R, Vogelzang NJ, O’Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O, ALSYMPCA Investigators (2013) Alpha emitter 223Ra and survival in metastatic prostate cancer. N Engl J Med 369:213–223
Wissing MD, van Leeuwen FWB, van der Pluijm G, Gelderblom H (2013) 223Ra chloride: extending life in prostate cancer patients by treating bone metastases. Clin Cancer Res 19:5822–5827
Xofigo product information (2013) U.S. Xofigo Web site: www.xofigo-us.com/product-information/. Accessed 18 Nov 2013
Henriksen G, Hoff P, Alstad J, Larsen RH (2001) 223Ra for endoradiotherapeutic applications prepared from an immobilized 227Ac/227Th source. Radiochim Acta 89:661–666
Guseva LI, Dogadkin NN (2008) A tandem generator for production and isolation of short-lived α-radionuclides Ra, Pb and Bi in EDTA solutions. Radiochemistry 50:310–315
Guseva LI (2009) A tandem generator system for production of 223Ra and 211Pb/211Bi in DTPA solutions suitable for potential application in radiotherapy. J Radioanal Nucl Chem 281:577–583
Guseva LI, Tikhomirova GS, Dogadkin NN (2004) An 227Ac-211Pb generator for test experiments of solution chemistry of element 114. J Radioanal Nucl Chem 260:167–172
Acknowledgments
The authors are grateful to Head of the Laboratory of Radiochemistry GEOKHI RAS Dr. Yury M. Kulyako for helpful discussions and support; Dr. Dmitry A. Malikov and Dr. Trofim I. Trofimov for their kind help with the alpha-spectrometric measurements.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mokhodoeva, O., Guseva, L. & Dogadkin, N. Isolation of generator-produced 223Ra in 0.9-% NaCl solutions containing EDTA for direct radiotherapeutic studies. J Radioanal Nucl Chem 304, 449–453 (2015). https://doi.org/10.1007/s10967-014-3777-7
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10967-014-3777-7